Venus Remedies Ltd has reported that the Drug Controller General of India (DCGI) has granted approval to its fixed dose cephalosporin combo with an amino-glycoside. The product will be launched very shortly in India.

This third R&D product will be marketed under a strategic tie-up with leading Indian pharma companies, in the Rs 4 billion domestic markets.

The company's plans to take this product to the international market, as well, a company release said.

The product is expected to cut the treatment time by half to what it is at present for patients suffering from Hospital Acquired Pneumonia (HAP).

The company has already filed patent applications for worldwide protection of its patent rights, the release added.